Latest news with #multinationalfirms
National Post
18 hours ago
- Business
- National Post
Market to Grow by 12.1% to Reach $6.97 Billion this Year - Investment Opportunities to 2029
Article content DUBLIN — The 'Canada Diabetes Devices and Therapeutics Market Investment Opportunities – Q2 2025 Update' report has been added to offering. Article content The diabetes market in Canada is expected to grow by 12.1% on annual basis to reach US$6.97 billion in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 12.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 10.0% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 6.22 billion to approximately USD 11.37 billion. Article content This report provides a detailed data-centric analysis of the diabetes industry in Canada, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. Article content The diabetes devices and therapeutics market in Canada comprises established multinational firms and emerging domestic players. A structured healthcare system with defined reimbursement pathways supports traditional and digital solutions. The Canadian diabetes devices and therapeutics market is characterized by a blend of multinational leaders and emerging technology-driven entrants. Recent strategic partnerships, mergers, and acquisitions indicate a move toward more integrated care solutions. In the coming years, competitive dynamics are expected to intensify, driven by consolidation and a focused shift toward digital integration and regulatory compliance. Article content The Canadian market is experiencing significant shifts, with increased CGM adoption, digital integration, advanced therapeutic systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures across provincial healthcare systems. Article content Expand Continuous Glucose Monitoring Usage Article content Canadian healthcare systems are broadening the use of continuous glucose monitoring (CGM) devices across several provinces. Provincial pilot programs in regions such as Ontario and British Columbia are incorporating CGM into routine diabetes care. Adjustments in provincial reimbursement policies and recent clinical studies from Canadian health agencies support wider CGM use. Recent publications have highlighted a shift in clinical practice toward data-driven patient monitoring. The adoption of CGM is expected to intensify as more provinces expand coverage and integrate real-time data into care protocols. Enhanced patient monitoring may improve diabetes management outcomes over the medium term. Article content Digital health platforms that support remote monitoring and telemedicine are increasingly integrated into diabetes management in Canada. Several regional healthcare systems have initiated digital dashboards to consolidate patient data for clinical decision-making. Government initiatives to improve telehealth services and recent shifts in healthcare delivery models are driving digital integration. Recent publications underscore provincial health ministries' investments in digital infrastructure. The integration of digital tools is projected to grow, supporting real-time care adjustments and enhanced data sharing among providers. This trend is expected to intensify as digital health reshapes chronic disease management. Article content Advance Therapeutic Delivery Systems Article content Advanced therapeutic devices such as smart insulin pens and connected insulin pumps are being tested in clinical settings across Canada. Pilot programs in select provinces have assessed these devices for precise dosing and improved treatment adherence. Recent technological improvements and research findings from Canadian institutions support the development of these systems. Funding and innovation incentives from provincial health programs are fostering the introduction of these therapeutic tools. Adoption will likely grow as clinical evidence and reimbursement models evolve, integrating these devices into standard practice. The trend is expected to intensify gradually, influencing treatment protocols in diabetes care. Article content Regulatory and Reimbursement Models Article content Regulatory bodies in Canada are updating guidelines and reimbursement policies to accommodate new diabetes devices and therapeutics. Recent policy documents have outlined pathways for including digital health and connected devices in public healthcare programs. Broader cost-containment strategies and ongoing evaluations of digital health effectiveness drive regulatory adjustments. Publications from provincial health ministries and Health Canada provide context for these evolving frameworks. Clearer regulatory and reimbursement models are anticipated to further support device integration and market expansion. These changes are expected to have a progressive impact, offering more defined channels for innovation in diabetes management. Article content Key Competitors and New Entrants Article content Several longstanding multinational companies hold significant market share. They offer a range of devices, from continuous monitoring systems to therapeutic delivery tools, and maintain strategic relationships with provincial healthcare agencies. New market entrants, including technology-focused startups, are introducing digital health solutions that target remote monitoring and data integration. Recent publications indicate that pilot programs in provinces allow these entrants to demonstrate value. Article content Recent publications detail partnerships where established companies collaborate with digital health startups to enhance device connectivity and patient data analytics. Mergers and acquisitions have been noted as firms consolidate technical expertise and broaden their market offerings within the Canadian context. These strategic developments reshape the market by promoting integrated care solutions and streamlined regulatory compliance. Collaborative efforts are aligning product innovation with provincial healthcare priorities. Article content Future Competitive Dynamics (2-4 Years) Article content The competitive landscape is expected to evolve as strategic partnerships and consolidation efforts deepen. Companies will likely increase investments in digital health integration, balancing established market leaders with nimble entrants. Over the next 2-4 years, market consolidation and technology-driven innovation are anticipated to further define competitive positioning, with clear implications for patient management strategies. Article content Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Article content Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Article content Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Article content Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Article content Insulin Pumps Insulin Pens Insulin Syringes Article content Diabetes Devices and Therapeutics Market Share by Therapeutics Article content Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Article content Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Article content Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Article content Diabetes Devices and Therapeutics Market Share by Insulin Article content Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Article content Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs Article content GLP-1 Receptor Agonists Amylin Analogue Article content Diabetes Devices and Therapeutics Market Share by Combination Drugs Article content Combination Insulin Oral Combination Article content Diabetes Devices and Therapeutics Market Share by Route of Administration Article content Subcutaneous Intravenous Others Article content Diabetes Devices and Therapeutics Market Share by Type of Diabetes Article content Type 1 Diabetes Type 2 Diabetes Article content Diabetes Devices and Therapeutics Market Share by Distribution Channels Article content Online Pharmacies Hospital Pharmacies Retail Pharmacies Article content Diabetes Devices and Therapeutics Market Share by End User Article content Hospitals Diabetes Clinics Homecare Article content Key Attributes: Article content Report Attribute Details No. of Pages 50 Forecast Period 2025 – 2029 Estimated Market Value (USD) in 2025 $7.77 Billion Forecasted Market Value (USD) by 2029 $11.37 Billion Compound Annual Growth Rate 10.0% Regions Covered Canada Article content For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Article content Article content Article content Article content Article content Contacts Article content Article content
Bloomberg
10-06-2025
- Business
- Bloomberg
Ireland Needs Fiscal Rule as Economic Risk Grows, Watchdog Warns
The Irish government should commit to a domestic fiscal rule so it can better plan spending as the economy enters uncertain territory, the state's fiscal watchdog warned. A global trade war stoked by US President Donald Trump is likely to have an outsized impact on Ireland, the strategic tax base for several multinational firms. Sticking to a fiscal rule would set a sustainable growth rate for spending net of tax changes, the Irish Fiscal Advisory Council said in its June fiscal assessment report.
Irish Times
06-06-2025
- Business
- Irish Times
Corporate tax take tumbles 30% for May with €1.1bn less over same month last year
The State's corporate tax receipts fell 30 per cent last month, with the exchequer collecting €1.1 billion less in May compared to the same month last year. Downplaying the decline, the Department of Finance attributed it to 'once-off factors' which, it said, boosted receipts last year and distorted the year-on-year comparison. The latest exchequer returns for May indicated the Government collected €2.5 billion in corporate taxes last month, compared to almost €3.6 billion last year. Minister for Finance Paschal Donohoe said May was among the more important months for tax revenues and the steady growth in most tax headings pointed to an economy 'that is in a relatively good position'. READ MORE While the drop in corporate tax could be attributed to one-off factors, he said, it highlighted the degree of concentration in the corporate tax base where a small number of multinational firms 'can significantly impact on the overall tax yield'. 'In a context of unprecedented uncertainty in the international economic landscape, this serves as a timely reminder of Ireland's exposure to changes in the global trading environment, and of the vital importance of adhering to a sensible and sustainable budgetary strategy,' he said. Meanwhile, the European Central Bank (ECB) confirmed its latest interest rate cut yesterday. For tens of thousands of mortgage holders, the eighth cut in the last year means they have seen the annual cost of their home loans fall by about €2,000. However, the downward rate cycle appears to be coming to an end. ECB president Christine Lagarde confirmed as much when she said that 'at the current level of interest rates, we believe that we are in a good position to navigate the uncertain conditions that will be coming up'. When asked if the bank was on the cusp of declaring victory in its battle against inflation, she replied that 'victory laps are always nice, but there is always another battle.' Those who will be first in line to benefit from the latest rate cut will be about 126,000 tracker mortgage holders. Each rate cut of 0.25 per cent is worth about €13 to this cohort, with the eight cuts over the last 12 months equating to savings of just under €2,000 over a year for someone with an outstanding home loan of €150,000. Although there is speculation that September will be marked by a further rate cut, the ECB said it would 'follow a data-dependent and meeting-by-meeting approach to determining the appropriate monetary policy stance' and stressed it was not committing to a particular rate path. Separate figures on Thursday from the Central Statistics Office pointed to economic growth of almost 10 per cent in the first quarter, up from a previous estimate of 3 per cent, as exporters rushed to get merchandise into the US in advance of the imposition of tariffs. Since April 5th, goods imported from all countries into the US have been subject to a 10 per cent tariff, while US president Donald Trump has put a stay on a possible 50 per cent tariff on all EU imports until next month. Pharma accounts for the lion's share of Irish goods exports to the US, and companies in the sector here have been fast-tracking products to avoid the tariffs. The pharma-dominated industry sector expanded by 17.1 per cent in the first quarter compared with the previous three-month period. By contrast, the domestic economy grew by just 0.8 per cent.
